Login to Your Account



Financings Roundup

Ariad Pads Cash with $300M For Iclusig Launch, Clinic Work

By Jennifer Boggs
Managing Editor

Thursday, January 24, 2013
financings_resized.jpg

A month after the earlier-than-expected approval of Iclusig (ponatinib) in chronic myelogenous leukemia (CML), Ariad Pharmaceuticals Inc. is taking advantage of the current public markets to more than double its cash balance. (See BioWorld Today, Dec. 17, 2012.)

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription